Latest news for Argus Worldwide (OTC:ARGW) Stock

Argus Worldwide Corp is a United States based portfolio management and investment company. Its strategic goals are focused on investment initiatives in the digital, IT and healthcare sectors. The group is intended to design, develop and operate an internet platform for a desktop computer and mobile use. It is also involved in the pharmaceutical business.

ARGUS WORLDWIDE CORP by Argus Worldwide Corp.

Argus Worldwide Corp

Piper Sandler analyst Matt O'Brien maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $235 to $250.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Penumbra, Raises Price Target to $250

WIIM

CING

Cingulate shares are trading higher after Maxim Group upgraded the stock from Hold to Buy.

Trading Ideas

$BTC

CNBC Halftime Report Final Trades: CNX Resources Corp, EQT Corp, Bitcoin - United States Dollar

Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) stock is moving higher on Wednesday after the company announced its purchase agreements and lease amendments were approved by the <a href="https://www.benzinga.com//node/42087351">Denton City Council on Nov. 19</a>.
The Details: Originally, Core Scientific leased about 31 acres of city-owned land and had access to 297 megawatts (MW) of power. Under the newly approved agreements, Core Scientific has expanded its lease to approximately 78 acres and increased its power access to 394 MW.
&#8220;Denton has been home to one of our most advanced data centers, and now we expect it will host one of the largest GPU supercomputers in North America, powering artificial intelligence,&#8221; said Adam Sullivan, Core Scientific CEO.
 &#8220;We have had a great experience operating in Denton and are grateful for the strong support we&#8217;ve received from the city staff and community members. We look forward to continuing our partnership with the City of Denton as we expand our infrastructure to support high-performance computing.&#8221;
The expansion is expected to result in a $6.1 billion investment in real property.
How To Buy Core Scientific Shares
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Core Scientific's case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
See Also: <a href="https://www.benzinga.com/24/11/42079585/meta-google-and-microsoft-bet-big-on-ai-with-skyrocketing-capex-budgets-but-jensen-huangs-nvidia-poised-to-be-the-biggest-winner-says-analyst-only-game-in-town-with-1-trillion-of-ai-capex">Dan Ives Expects &#8216;Drop The Mic Performance&#8217; Tomorrow From Nvidia: Here&#8217;s Why</a>
CORZ Price Action: At the time of writing, Core Scientific shares are moving 5.34% higher at $17.35, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Shutterstock

Movers

Core Scientific, Inc. - Class A Common Stock

CORZ

What's Going On With Core Scientific Shares Wednesday?

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and lowers the price target from $7 to $2.

APTO

HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Lowers Price Target to $2

In the last three months, 6 analysts have published ratings on ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $17.18, a high estimate of $25.00, and a low estimate of $10.50. Experiencing a 1.26% decline, the current average is now lower than the previous average price target of $17.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1732125669_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive ZIM Integrated Shipping is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omar Nokta</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Alexia Dogani</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$13.90</td>
<td>$12.30</td>
</tr>
<tr>
<td>Omar Nokta</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Alexia Dogani</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Underweight</td>
<td>$10.50</td>
<td>-</td>
</tr>
<tr>
<td>Muneeba Kayani</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$13.70</td>
<td>$12.20</td>
</tr>
<tr>
<td>Alexia Dogani</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$15.00</td>
<td>$12.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ZIM Integrated Shipping. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ZIM Integrated Shipping compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for ZIM Integrated Shipping's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ZIM Integrated Shipping's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZIM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ZIM Integrated Shipping analyst ratings.</a>
<h2>Get to Know ZIM Integrated Shipping Better</h2>
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
<h3>Breaking Down ZIM Integrated Shipping's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: ZIM Integrated Shipping's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 47.57%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: ZIM Integrated Shipping's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 19.21%, the company may face hurdles in effective cost management.
Return on Equity (ROE): ZIM Integrated Shipping's ROE stands out, surpassing industry averages. With an impressive ROE of 13.67%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.98%, the company showcases effective utilization of assets.
Debt Management: ZIM Integrated Shipping's debt-to-equity ratio surpasses industry norms, standing at 1.94. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About ZIM Integrated Shipping Stock

Benzinga's options scanner just detected over 8 options trades for HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) summing a total amount of $532,222.
At the same time, our algo caught 6 for a total amount of 637,251.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $315.0 to $335.0 for HCA Healthcare over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for HCA Healthcare's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of HCA Healthcare's whale trades within a strike price range from $315.0 to $335.0 in the last 30 days. 
<h3>HCA Healthcare Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732125645_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.6</td>
<td>$8.4</td>
<td>$8.6</td>
<td>$325.00</td>
<td>$215.7K</td>
<td align="right">86</td>
<td align="right">262</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.6</td>
<td>$9.5</td>
<td>$9.5</td>
<td>$330.00</td>
<td>$139.7K</td>
<td align="right">97</td>
<td align="right">150</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$330.00</td>
<td>$95.9K</td>
<td align="right">97</td>
<td align="right">259</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$18.4</td>
<td>$18.3</td>
<td>$18.4</td>
<td>$335.00</td>
<td>$80.9K</td>
<td align="right">2</td>
<td align="right">36</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.8</td>
<td>$7.2</td>
<td>$7.2</td>
<td>$315.00</td>
<td>$72.7K</td>
<td align="right">410</td>
<td align="right">222</td>
</tr>
</tbody>
</table>

<h3>About HCA Healthcare</h3>
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
Following our analysis of the options activities associated with HCA Healthcare, we pivot to a closer look at the company's own performance.
<h3>Where Is HCA Healthcare Standing Right Now?</h3>
<ul>
<li>With a volume of 505,703, the price of HCA is down -1.79% at $329.1. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 69 days.</li>
</ul>
<h3>What The Experts Say On HCA Healthcare</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $401.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on HCA Healthcare, which currently sits at a price target of $395. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on HCA Healthcare, which currently sits at a price target of $392. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for HCA Healthcare, targeting a price of $420. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on HCA Healthcare, maintaining a target price of $400. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on HCA Healthcare, maintaining a target price of $400. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest HCA Healthcare options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Spotlight on HCA Healthcare: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ULTA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 24 uncommon options trades for Ulta Beauty.
This isn't normal.
The overall sentiment of these big-money traders is split between 29% bullish and 54%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $391,914, and 18 are calls, for a total amount of $1,122,649.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $450.0 for Ulta Beauty over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Ulta Beauty's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Ulta Beauty's substantial trades, within a strike price spectrum from $300.0 to $450.0 over the preceding 30 days.
<h3>Ulta Beauty Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732125640_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ULTA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$21.6</td>
<td>$21.1</td>
<td>$21.6</td>
<td>$310.00</td>
<td>$216.0K</td>
<td>152</td>
<td align="right">100</td>
</tr>
<tr>
<td>ULTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$109.7</td>
<td>$105.6</td>
<td>$107.4</td>
<td>$300.00</td>
<td>$107.4K</td>
<td>1.4K</td>
<td align="right">70</td>
</tr>
<tr>
<td>ULTA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$108.5</td>
<td>$105.2</td>
<td>$107.6</td>
<td>$300.00</td>
<td>$107.1K</td>
<td>1.4K</td>
<td align="right">50</td>
</tr>
<tr>
<td>ULTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$107.6</td>
<td>$105.6</td>
<td>$107.6</td>
<td>$300.00</td>
<td>$86.0K</td>
<td>1.4K</td>
<td align="right">60</td>
</tr>
<tr>
<td>ULTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$110.4</td>
<td>$103.4</td>
<td>$107.6</td>
<td>$300.00</td>
<td>$86.0K</td>
<td>1.4K</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About Ulta Beauty</h3>
With 1,385 stores at the end of fiscal 2023 and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the US. The firm offers makeup (41% of 2023 sales), fragrances, skin care (19% of sales), and hair care products (19% of sales), and bath and body items. Ulta offers private-label products and more than 600 individual brands. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Having examined the options trading patterns of Ulta Beauty, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Ulta Beauty</h3>
<ul>
<li>With a trading volume of 392,950, the price of ULTA is up by 0.03%, reaching $342.27.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 15 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Ulta Beauty, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ULTA

A Closer Look at Ulta Beauty's Options Market Dynamics

In the last three months, 11 analysts have published ratings on Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Procter &amp; Gamble, revealing an average target of $171.73, a high estimate of $191.00, and a low estimate of $159.00. Surpassing the previous average price target of $167.25, the current average has increased by 2.68%.
<img src="https://www.benzinga.com/files/images/story/2024/1732125637_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Procter &amp; Gamble. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$191.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Robert Ottenstein</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$164.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$159.00</td>
<td>-</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$174.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$186.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Michael Pohn</td>
<td>DZ Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$190.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Procter &amp; Gamble. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Procter &amp; Gamble compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Procter &amp; Gamble's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Procter &amp; Gamble's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Procter &amp; Gamble analyst ratings.</a>
<h2>About Procter &amp; Gamble</h2>
Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.
<h3>Understanding the Numbers: Procter &amp; Gamble's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Procter &amp; Gamble's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -0.61%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Procter &amp; Gamble's net margin excels beyond industry benchmarks, reaching 17.88%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Procter &amp; Gamble's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 7.73%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Procter &amp; Gamble's ROA excels beyond industry benchmarks, reaching 3.12%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.71, Procter &amp; Gamble adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

11 Analysts Have This To Say About Procter & Gamble

Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie.
Looking at options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $1,433,900 and 5, calls, for a total amount of $514,031.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $190.0 for AbbVie over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AbbVie's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale trades within a strike price range from $150.0 to $190.0 in the last 30 days. 
<h3>AbbVie Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732125634_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.06</td>
<td>$1.31</td>
<td>$1.38</td>
<td>$160.00</td>
<td>$1.2M</td>
<td>1.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$21.6</td>
<td>$21.55</td>
<td>$21.6</td>
<td>$150.00</td>
<td>$254.8K</td>
<td>14</td>
<td>118</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.4</td>
<td>$1.36</td>
<td>$1.4</td>
<td>$160.00</td>
<td>$145.9K</td>
<td>1.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.52</td>
<td>$190.00</td>
<td>$130.6K</td>
<td>207</td>
<td>380</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.1</td>
<td>$7.05</td>
<td>$7.05</td>
<td>$165.00</td>
<td>$69.7K</td>
<td>4.1K</td>
<td>116</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>Trading volume stands at 1,463,877, with ABBV's price up by 0.16%, positioned at $166.84.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 72 days.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $215.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on AbbVie with a target price of $231. 
&#x2A; In a cautious move, an analyst from Wolfe Research downgraded its rating to Outperform, setting a price target of $205. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on AbbVie with a target price of $200. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on AbbVie, which currently sits at a price target of $215. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on AbbVie with a target price of $224. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ABBV

Unpacking the Latest Options Trading Trends in AbbVie

Providing a diverse range of perspectives from bullish to bearish, 25 analysts have published ratings on Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">15</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Estee Lauder Cos and provided 12-month price targets. The average target is $96.16, accompanied by a high estimate of $130.00 and a low estimate of $70.00. A decline of 13.02% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1732125627_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Estee Lauder Cos is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$81.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$75.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Bryan Spillane</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jason English</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$75.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$81.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$76.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Christopher Carey</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$122.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Estee Lauder Cos. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Estee Lauder Cos compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Estee Lauder Cos's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Estee Lauder Cos's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Estee Lauder Cos analyst ratings.</a>
<h2>Delving into Estee Lauder Cos's Background</h2>
Estee Lauder is a leader in the global prestige beauty market, participating across skin care (51% of fiscal 2024 sales), makeup (29%), fragrance (16%), and hair care (4%) categories, with top-selling brands such as Estee Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 30% of revenue from the Americas, 39% from Europe, the Middle East and Africa (including travel retail), and 31% from Asia-Pacific. Estee Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
<h3>Estee Lauder Cos: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Challenges: Estee Lauder Cos's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -4.46%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -4.64%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Estee Lauder Cos's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.0%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Estee Lauder Cos's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.73% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Estee Lauder Cos's debt-to-equity ratio stands notably higher than the industry average, reaching 1.97. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Estee Lauder Cos Through The Eyes Of 25 Analysts

Sadot Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) shares are trading higher by 16.6% to $3.52 during Wednesday&#8217;s session. The CEO and CIO disclosed they purchased shares in the company through <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=102691&amp;ref=318734230&amp;type=PDF&amp;symbol=SDOT&amp;cdn=0db81d635e71280aa421767937f25e3d&amp;companyName=Sadot+Group+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-11-20">Form 4 filings</a>.
Why This Matters: Insider buying often signals confidence in a company's future prospects, as executives typically only purchase stock when they believe the shares are undervalued or poised for growth. 
The filings revealed that both the CEO and CIO acquired shares in the open market, which investors can sometimes interpret as a positive signal of strong internal belief in Sadot Group's ongoing business strategy.
Sadot Group, which specializes in global trade of agricultural products and services, has been working on expanding its reach in key emerging markets. This insider buying could reflect the leadership&#8217;s optimism about the company's growth potential moving forward.
Read Also: <a href="https://www.benzinga.com/news/global/24/11/42092678/whats-going-on-with-faraday-future-intelligent-electric-stock">What&#8217;s Going On With Faraday Future Intelligent Electric Stock?</a>
<h2 class="wp-block-heading">How To Buy SDOT Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Sadot Group&#8217;s case, it is in the Consumer Staples sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SDOT has a 52-week high of $6.94 and a 52-week low of $2.24.

SDOT

Sadot Group (SDOT) Stock Is Up 16% Today: What's Going On?

Throughout the last three months, 8 analysts have evaluated United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated United Rentals and provided 12-month price targets. The average target is $886.12, accompanied by a high estimate of $955.00 and a low estimate of $565.00. Witnessing a positive shift, the current average has risen by 10.13% from the previous average price target of $804.62.
<img src="https://www.benzinga.com/files/images/story/2024/1732125610_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of United Rentals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Eade</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$880.00</td>
<td>$840.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$955.00</td>
<td>$930.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$565.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$955.00</td>
<td>$954.00</td>
</tr>
<tr>
<td>Ross Gilardi</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$910.00</td>
<td>$800.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$930.00</td>
<td>$860.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$954.00</td>
<td>$873.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$940.00</td>
<td>$780.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to United Rentals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of United Rentals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Rentals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into United Rentals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/URI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Rentals analyst ratings.</a>
<h2>Delving into United Rentals's Background</h2>
United Rentals is the world's largest equipment rental company. It principally operates in the United States and Canada, where it commands approximately 15% share in a highly fragmented market. It serves three end markets: general industrial, commercial construction, and residential construction. Like its peers, United Rentals historically has provided its customers with equipment that was intermittently used, such as aerial equipment and portable generators. As the company has grown organically and through hundreds of acquisitions since it went public in 1997, its catalog (fleet size of $22 billion) now includes a range of specialty equipment and other items that can be rented for indefinite periods.
<h3>Key Indicators: United Rentals's Financial Health</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining United Rentals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.03% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: United Rentals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 17.74%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): United Rentals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.4%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): United Rentals's ROA stands out, surpassing industry averages. With an impressive ROA of 2.53%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: United Rentals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.68.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Have This To Say About United Rentals

C3.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) shares are trading lower on Wednesday despite the positive news of an expanded <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42094164/c3-ai-and-capgemini-extend-partnership-to-accelerate-enterprise-ai-for-business-transformation" rel="noreferrer noopener">partnership with </a><a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42094164/c3-ai-and-capgemini-extend-partnership-to-accelerate-enterprise-ai-for-business-transformation" rel="noreferrer noopener">Capgemini</a><a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42094164/c3-ai-and-capgemini-extend-partnership-to-accelerate-enterprise-ai-for-business-transformation" rel="noreferrer noopener">.</a>
This new collaboration aims to accelerate the delivery of Enterprise AI solutions across various industries, helping clients enhance efficiency, productivity, and reduce costs.
By combining C3.ai&#8217;s AI applications with Capgemini&#8217;s industry expertise and global implementation capabilities, the two companies will tailor AI solutions for sectors such as life sciences, energy, utilities, government, banking, and manufacturing.
Capgemini will further strengthen this partnership by expanding its dedicated global practice for C3.ai, focusing on delivering scalable AI solutions with rapid time-to-value for joint clients.
See Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/global/24/11/42056728/nvidia-modestly-at-risk-amid-ai-chip-concerns-analyst-notes-momentum-money-swirling-around-sells-first-asks-questions-later" rel="noreferrer noopener">Nvidia &#8216;Modestly At Risk&#8217; Amid AI Chip Concerns, Analyst Notes: Momentum Money Swirling Around &#8216;Sells First, Asks Questions Later&#8217;</a>
C3.ai&#8217;s Chairman and CEO, Thomas M. Siebel, emphasized that the collaboration will empower organizations to operate more efficiently and innovate faster, providing a competitive edge through Enterprise AI.
&#8220;Our partnership with Capgemini dramatically expands our service and delivery capacity, ensuring the continued success of our growing customer base at global scale,&#8221; Siebel said.
Additionally, C3.ai made headlines yesterday when it announced a strategic alliance with Microsoft <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/11/42069266/c3-ai-stock-is-surging-tuesday-whats-going-on" rel="noreferrer noopener">at the Microsoft Ignite conference.</a>
The partnership, which builds on their existing collaboration, aims to accelerate the adoption of Enterprise AI on Microsoft Azure.
The new agreement positions Microsoft as the preferred cloud provider for C3.ai&#8217;s offerings, and C3.ai as a preferred AI application software provider on Azure. Both companies will focus on technical integration, product development, and joint marketing efforts to drive AI adoption.
These strategic moves highlight C3.ai&#8217;s commitment to expanding its AI solutions across industries and accelerating global growth.
Price Action: AI shares traded lower by 2% at $32.30 at last check Wednesday.
Photo via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42085436/target-q3-earnings-supply-chain-chaos-hits-bottomline-slashes-annual-profit-outlook-stock-tanks" target="_blank" rel="noreferrer noopener">Target Q3 Earnings: Supply Chain Chaos Hits Bottomline, Slashes Annual Profit Outlook, Stock Tanks</a></li>
</ul>

Equities

General

What's Going On With C3.ai Stock Wednesday?

Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) shares are trading higher on Wednesday after the company announced that it entered into a strategic collaboration with SeaTrepid.
The Details: The goal of the collaboration is to integrate and test its ToolKITT software on a Remotely Operated Vehicle (ROV) in SeaTrepid&#8217;s fleet.
Specifically, Nauticus will implement a perpetual license of its ToolKITT software onto an ROV, with SeaTrepid providing access to its facilities and workforce to assist with testing. As a result, SeaTrepid will enhance its ROV services, gaining a competitive edge, while Nauticus will benefit from ongoing annual software maintenance revenue after deployment.
&#8220;We are thrilled to work with&nbsp;Bob Christ&nbsp;and the team at SeaTrepid. Together, we aim to revolutionize subsea operations by advancing autonomous ROV capabilities,&#8221; said John Gibson, CEO and President of Nauticus Robotics.
&#8220;By equipping SeaTrepid&#8217;s ROVs with ToolKITT, we can deliver significant efficiency gains, including reduced CO2 emissions, faster mission completion times, and fewer operator-related delays. This collaboration represents an exciting entry point for ToolKITT into the broader ROV market, building on its recent success on the Aquanaut Mark 2 vehicle earlier this year.&#8221;
How To Buy Nauticus Robotics Shares
By now you're likely curious about how to participate in the market for Nauticus Robotics &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Nauticus Robotics, which is trading at $1.05 as of publishing time, $100 would buy you 95.24 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
See Also: <a href="https://www.benzinga.com/24/11/42079585/meta-google-and-microsoft-bet-big-on-ai-with-skyrocketing-capex-budgets-but-jensen-huangs-nvidia-poised-to-be-the">Dan Ives Expects &#8216;Drop The Mic Performance&#8217; Tomorrow From Nvidia: Here&#8217;s Why</a>
KITT Price Action: At the time of writing, Nauticus Robotics stock is trading 12.1% higher at $1.02, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Unsplash

KITT

What's Going On With Nauticus Robotics Shares Wednesday?

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Buy and maintains $617 price target.

Reiteration

ARGX

HC Wainwright & Co. Reiterates Buy on argenx, Maintains $617 Price Target

<a href="https://www.gov.uk/government/news/tribunal-fines-drug-firms-69m-for-excessive-pricing-after-cma-investigation#:~:text=It%20found%20that%20both%20firms,rose%20by%20780%2D1%2C600%25" title="https://www.gov.uk/government/news/tribunal-fines-drug-firms-69m-for-excessive-pricing-after-cma-investigation#:~:text=It%20found%20that%20both%20firms,rose%20by%20780%2D1%2C600%25">https://www.gov.uk/government/news/tribunal-fines-drug-firms-69m-for-excessive-pricing-after-cma-investigation#:~:text=It%20found%20that%20both%20firms,rose%20by%20780%2D1%2C600%25</a>.

Biotech

UK Tribunal Fines Pfizer And Flynn £69M For Excessive Pricing Of Epilepsy Drug, Finds Firms Abused Dominant Market Positions From 2012-2016

On Wednesday, the FDA approved UCB SA&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>) Bimzelx&nbsp;(bimekizumab-bkzx) for adults with moderate to severe hidradenitis suppurativa (HS).
Bimekizumab-bkzx is the first and only approved medicine <a target="_blank" href="https://www.ucb.com/stories-media/Press-Releases/article/UCB-receives-US-FDA-approval-for-BIMZELXR-bimekizumab-bkzx-as-the-first-IL-17A-and-IL-17F-inhibitor-for-adults-with-moderate-to-severe-hidradenitis-suppurativa" rel="noreferrer noopener">designed</a> to selectively inhibit interleukin 17F (IL-17F) in addition to interleukin 17A (IL-17A).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40549706/belgium-based-pharma-firm-ucb-to-offload-china-neurology-allergy-business-for-680m-to-asset-manag" rel="noreferrer noopener">Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies</a>
Hidradenitis suppurativa is a chronic inflammatory skin disease.
The main symptoms are nodules, abscesses, and pus-discharging fistulas, i.e., channels leading out of the skin, typically in the armpits, groin, and buttocks.
Data from two Phase 3 studies, BE HEARD I and BE HEARD II, support the approval.
Results showed that a higher proportion of patients treated with bimekizumab-bkzx vs. placebo achieved a 50% or greater improvement in signs and symptoms at Week 16, as measured by HiSCR50, the primary endpoint in both trials.
Bimekizumab-bkzx treatment also resulted in clinically meaningful improvements in the key ranked secondary endpoint, HiSCR75, vs. placebo at Week 16. Clinical responses were sustained to Week 48.
This FDA approval of bimekizumab-bkzx for adults with moderate to severe hidradenitis suppurativa follows its recent approvals for the treatment of adults with active psoriatic arthritis, adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation and adults with active ankylosing spondylitis.
Bimekizumab-bkzx was first approved in the U.S. in October 2023 for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42089637/israel-based-cargo-shipping-company-zim-integrated-smashes-estimates-with-626-ebitda-growth-and-upgraded-2024-outlook" target="_blank" rel="noreferrer noopener">Israel-Based Cargo Shipping Company ZIM Integrated Smashes Estimates With 626% EBITDA Growth, Upgrades 2024 Outlook</a></li>
</ul>
Image via Adobe Stock

Health Care

UCBJF

UCBJY

FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and maintains $14 price target.

SAGE

HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $14 Price Target

WeRide shares are trading lower after the company announced its Robosweeper S6 and Robosweeper S1 have officially commenced operations at the Marina Coastal Drive and Esplanade in Singapore.

Comments

Argus Worldwide

News

Latest news for Argus Worldwide (OTC:ARGW) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga